Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Shobha H. Ganji"'
Publikováno v:
Journal of Lipid Research, Vol 53, Iss 5, Pp 941-950 (2012)
The lipidation of apoA-I in liver greatly influences HDL biogenesis and plasma HDL levels by stabilizing the secreted apoA-I. Niacin is the most effective lipid-regulating agent clinically available to raise HDL. This study was undertaken to identify
Externí odkaz:
https://doaj.org/article/93e8fb8fc5c34ba38680dc2a67097473
Publikováno v:
Journal of Lipid Research, Vol 51, Iss 8, Pp 2211-2222 (2010)
Pioglitazone, a hypoglycemic agent, has been shown to increase plasma HDL cholesterol, but the mechanism is incompletely understood. We further investigated effects of pioglitazone on transcriptional regulation of apolipoprotein (apo)A-I gene and fun
Externí odkaz:
https://doaj.org/article/2e1a662a4fc24e7c90b3b353e4a079fd
Autor:
Shobha H. Ganji, S. Tavintharan, Daming Zhu, Yiding Xing, Vaijinath S. Kamanna, Moti L. Kashyap
Publikováno v:
Journal of Lipid Research, Vol 45, Iss 10, Pp 1835-1845 (2004)
Niacin is a widely used lipid-regulating agent in dyslipidemic patients. Previously, we have shown that niacin inhibits triacylglycerol synthesis. In this report, using HepG2 cells, we have examined the effect of niacin on the mRNA expression and mic
Externí odkaz:
https://doaj.org/article/dd0ffdc4d8c34c1da895b7e8d2e6fae6
Publikováno v:
Journal of Clinical Lipidology. 13:873-879
Niacin has been widely used clinically for over half a century for dyslipidemia. Recent new evidence indicates that niacin may be useful in the treatment of nonalcoholic fatty liver disease (NAFLD) and its sequential complications including nonalcoho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a00bbb663c6e339f8af0aba10561f9b
https://doi.org/10.1016/j.jacl.2019.10.006
https://doi.org/10.1016/j.jacl.2019.10.006
Publikováno v:
Archives of Gastroenterology Research. 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23e7834d9694eae5be0e1724054bf652
https://doi.org/10.33696/gastroenterology.1.015
https://doi.org/10.33696/gastroenterology.1.015
Publikováno v:
Atherosclerosis. 235:554-561
Objectives Leukocyte myeloperoxidase (MPO) is a major player in the pathogenesis of various chronic diseases including atherosclerosis. This study proposes the novel concept that niacin, through reactive oxygen species (ROS)-mediated signaling, decre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afaf36fdc9d2d8e1681e66a273a97d29
https://doi.org/10.1016/j.atherosclerosis.2014.05.948
https://doi.org/10.1016/j.atherosclerosis.2014.05.948
Publikováno v:
Current Opinion in Lipidology. 24:239-245
Purpose of review This review focuses on the current understanding of the physiological mechanisms of action of niacin on lipid metabolism and atherosclerosis. Recent findings Emerging findings indicate that niacin decreases hepatic triglyceride synt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a531c8ee15902aa07223e4806d9d930c
https://doi.org/10.1097/mol.0b013e3283613a68
https://doi.org/10.1097/mol.0b013e3283613a68
Publikováno v:
Current Cardiovascular Risk Reports. 7:102-107
Myeloperoxidase (MPO), a member of the peroxidase family, emerged as a major player in the initiation and propagation of atherosclerotic cardiovascular disease (CVD). Evidence for its role in atherosclerosis include that MPO: a) induces endothelial d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f53f5426a32447985c5826e5debbc435
https://doi.org/10.1007/s12170-013-0291-3
https://doi.org/10.1007/s12170-013-0291-3
Publikováno v:
Journal of Lipid Research, Vol 53, Iss 5, Pp 941-950 (2012)
The lipidation of apoA-I in liver greatly influences HDL biogenesis and plasma HDL levels by stabilizing the secreted apoA-I. Niacin is the most effective lipid-regulating agent clinically available to raise HDL. This study was undertaken to identify
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6903d6731dcc6e4857de02a511703879
http://www.sciencedirect.com/science/article/pii/S0022227520392245
http://www.sciencedirect.com/science/article/pii/S0022227520392245
Autor:
Keith C. Norris, Stanislav Shelkovnikov, Nosratola D. Vaziri, Vaijinath S. Kamanna, Shobha H. Ganji
Publikováno v:
American Journal of Nephrology. 35:114-119
Background/Aims: Intravenous (IV) iron preparations are widely used in the management of anemia in ESRD populations. Recent changes in reimbursement policy have dramatically increased the use of IV iron to lower the use of costly erythropoiesis-stimu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::021f588eefb1e0ae2fb2b159298b13f6
https://doi.org/10.1159/000334939
https://doi.org/10.1159/000334939